GlassScriptPhysician profile
Bhaskar N Raju
NPI 1558397620
$11,081.98
in general payments reported to CMS, 2019-2025
33 companies · $1,069 in 2025
The $1,069 reported for 2025 was more than what 86% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $864 · 2020: $557 · 2021: $2,114 · 2022: $1,361 · 2023: $3,361 · 2024: $1,757 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,186.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,617.85 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $883.89 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $849.91 | 2021-2025 | Caplyta |
| Alkermes, INC. | $663.65 | 2019-2025 | Lybalvi, Aristada, Vivitrol |
| Ironshore Pharmaceuticals INC. | $605.10 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $567.26 | 2019-2023 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $487.98 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Sunovion Pharmaceuticals INC. | $477.20 | 2019-2022 | |
| Lundbeck LLC | $450.58 | 2019-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $450.10 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Takeda Pharmaceuticals U.S.A., INC. | $432.53 | 2019-2024 | Trintellix |
| Corium, LLC | $430.95 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $423.36 | 2021-2025 | Qelbree, Qelbree |
| Allergan, INC. | $328.85 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $311.75 | 2022-2025 | Ingrezza |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $178.81 | 2023 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $166.02 | 2019-2024 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $154.30 | 2024-2025 | Cobenfy |
| Validus Pharmaceuticals LLC | $127.26 | 2019-2025 | Raldesy, Equetro |
| Adlon Therapeutics L.P. | $86.34 | 2019-2021 | |
| Neos Therapeutics, LP | $78.55 | 2019-2022 | |
| Almatica Pharma LLC | $60.98 | 2024-2025 | Loreev Xr |
| Asd Specialty Healthcare, LLC | $49.80 | 2019 | |
| Brainsway USA INC | $41.17 | 2023-2024 | Brainsway Deep Tms System |
| Collegium Pharmaceutical, INC. | $34.44 | 2025 | Jornay Pm |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.60 | 2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $16.97 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.92 | 2023 | Quviviq |
| Vertical Pharmaceuticals, LLC | $16.36 | 2024 | Relexxii |
| Indivior INC. | $14.69 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.57 | 2019 | |
| Shire North American Group INC | $14.32 | 2019 | |
| Neuronetics, INC. | $8.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhaskar Raju listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.